lesion. The mortality rate for surgical closure is negligible. However, the morbidity of anesthesia and thoracotomy, scar of surgery, and expense are disadvantages. During the past 25 years, Porstmann and colleagues1I2 and Rashkind and colleagues3-6 have developed transcatheter methods to close the patent ductus arteriosus. A double-disc, nonhooked prosthesis5'6 was used in several clinical trials by several groups of researchers.6-12 Although these methods have advantages over the surgical closure, the delivery catheters/ sheaths are quite large and bulky, requiring 18F (Porstmann's Ivalon plug), 11F (Rashkind's double-disc device for large ductuses), and 8F (Rashkind's doubledisc device for small ductuses) sheaths for implantation of the device across the patent ductus arteriosus. Furthermore, the Rashkind device is not suitable for patent ductus arteriosuses of all shapes and sizes (eg, tubular and short patent ductus arteriosuses and patent ductus arteriosuses larger than 7 mm). Sideris and colleagues13 developed an adjustable buttoned device, similar to their atrial septal defect closure device,14-16 that can be delivered via a 7F sheath. The purpose of this report is to present our experience with this adjustable buttoned device in occluding the patent ductus arteriosus in an attempt to assess safety and efficacy of this system.
Methods
During a 26-month period ending November 1992, 14 patients underwent transcatheter closure of patent ductus arteriosus with an adjustable buttoned device. The study was performed under a protocol for human use of the custom-made devices and was approved by institutional review board at each hospital (Table 1) . Informed consent was obtained from all parents. Patients were selected on the basis of standard criteria established for selection of patients for surgical treatment of patent ductus arteriosus. Only patients with clinical and laboratory features, including echocardiographic-Doppler studies, suggesting the need for surgical correction were chosen. No patients were excluded because of ductal size or anatomy.
The buttoned device system consists of three components: the occluder, the counter-occluder, and a delivery system, and is similar to the device used for occlusion of atrial septal defect.14-17 The occluder is made of a Teflon-coated wire skeleton covered with 1/16 in. polyurethane foam. The wire skeleton is x-shaped when unfolded; the wires can be made to position parallel for introduction into a 7F sheath. An important difference between this and the atrial septal defect device is the button loop. The length of the loop is 8 mm instead of a 2-mm loop. There are two knots (4 mm and 8 mm from the occluder) with incorporation of radiopaque material into the proximal knot (the knot farthest from the occluder) (Fig 1) . The counter-occluder is made up of a single-strand, Teflon-coated wire skeleton covered with a rhomboid-shaped polyurethane foam. A rubber piece is sutured in its center and becomes a buttonhole (Fig 1) . The device delivery system consists of (1) a Teflon-coated 0.035-in. guidewire (Cook, Inc, Bloomington, Ill), the loading wire, and (2) a folded 0.008-in. Nylon thread passing through the guidewire after having its core removed. This thread passes through the loop in the center of the occluder. The device is delivered through a 7F, long sheath (Cordis Corp, Miami, Fla, or Cook Inc). A 7F multi-A2 (Cordis) catheter (pusher) is used to advance the occluder and counter-occluder within the sheath.
The patients were sedated with a mixture of meperidine, promethazine, and chlorpromazine. This is supplemented with intermittent doses of midazolam to ensure adequate sedation. No sheath, the sheath was slowly withdrawn into the ductus, thus opening the occluder in the descending aorta at its junction with the ductus. The entire system was slowly withdrawn to ensure anchoring of the occluder on the descending aortic side of the ductus. Once in position, the sheath and the catheter tips were withdrawn into the main pulmonary artery. The catheter was removed while maintaining the tip of the sheath in the main pulmonary artery. The counter-occluder was then threaded over the guidewire, but within the sheath, and was delivered to the pulmonary artery side of the patent ductus arteriosus. Introduction of the knot (button) of the occluder loop through the rubber piece (buttonhole) of the counter-occluder was performed by simultaneously (gently) pulling the occluder against the ductus while advancing the counter-occluder with the long sheath. Verification that the knot has been pulled through the buttonhole was obtained by fluoroscopy aided by the radiopaque marker on the knot. Further pushing of the counter-occluder with the tip of the sheath while gently pulling the occluder was attempted in short ductuses so that the counter-occluder could pass beyond the nonopaque distal knot (closer to the occluder). After satisfactory buttoning, the loading wire was cut at the tip and withdrawn, leaving the nylon strands holding the occluder. The device was disconnected by pulling one of the two nylon strands, thus disconnecting the implanted device from the loading system. During both of these maneuvers, the long sheath was gently pressed against the device to prevent inadvertent dislodgment of the device. The long sheath was removed and replaced with a short, regular sheath in the femoral vein. Fifteen minutes after device implantation, oxygen saturation data and an aortic arch cineangiogram were recorded. Cefazolin (50 mg/kg) was administered intravenously and repeated at 6 and 12 hours after the procedure. Catheters and sheaths were removed, taking adequate precautions not to dislodge the device. Oral aspirin (5 to 10 mg* kg`. day-') was begun on the day after device implantation for preventing excessive aggregation of platelets on the device. Aspirin was discontinued 6 weeks later. Two-dimensional echocardiographic and Doppler (pulsed and color) studies were performed on the afternoon of the procedure; 1, 6, and 12 months following the procedure; and yearly thereafter.
The data are expressed as mean±SD. The Student's t test was used for comparison of the preclosure and postclosure echocardiographic measurements. Aortic arch angiography revealed no residual shunt (Figs 2 through 4) in 10 patients, and faint opacification of the pulmonary artery was seen in the remaining 4 children. Closure of the patent ductus arteriosus was accomplished successfully in all types20 of ductus (Table  2) , including tubular (Fig 2), conical (Fig 3) , and short or "aortopulmonary window" (Fig 4) types. One patient with residual shunt following previous Rashkind device also underwent successful closure with the adjustable buttoned device (Fig 5) . Careful auscultation following device implantation revealed no residual murmurs in 13 children; all of these children had grade II-III/VI continuous murmurs before transcatheter occlusion.
One child had a faint, continuous murmur (Table 2) . Echo-Doppler studies performed on the afternoon of device implantation revealed mild color flow disturbances in the pulmonary artery suggestive of small residual patent ductus arteriosus in 4 children ( the delivery catheters are large and bulky and required insertion of 13F to 28F sheaths into the femoral artery for implantation of Porstmann's Ivalon plug21 and insertion of 8F to llF sheaths into the femoral vein for placement of Rashkind's double-disc device.5-11 Although much improved, the 8F sheath, and certainly the 11F, is too bulky for use in infants and small children. Sideris and colleagues14 developed a buttoned device for closure of atrial septal defect. This device was modified by us into an adjustable button device for occluding the patent ductus arteriosus. These devices require a small sheath (7F) for delivery and can be used to close patent ductus arteriosuses of different lengths.
This device was initially used in experimental patent ductus arteriosus in piglets13 with success, and subsequently, we reported its successful use in a 5-year-old child.'9 The device can easily be delivered through a 7F sheath, thus making it more suitable in younger and smaller children, and it may have advantages over the other devices.
The adjustable device has a longer button loop (8 mm) with a radiopaque marker at the end (Fig 1) . In addition to this, there is another knot in the middle (Fig  1, nonradiopaque button) . Therefore, patent ductus arteriosuses ofvarious lengths and shapes,20 namely, the conical type, tubular, and short ("aortopulmonary window") ductuses can be effectively occluded with this device. The patent ductus arteriosuses that are not suitable (eg, short ["aortopulmonary window"] and tubular) for transcatheter occlusion by the Rashkind device can be occluded with the adjustable buttoned device. This device can be used for all sizes of ductuses, whereas the Rashkind device is not suitable for patent ductus arteriosuses larger than 7 mm. An additional advantage of the buttoned device is that it is positioned outside the ductus, totally isolating the entire ductus from circulation. Because of the small sheath required for device implantation and adjustability of the device to effect closure of all types of patent ductus arteriosuses, the adjustable buttoned device conceivably could be applicable for closure of the patent ductus arteriosus in all age groups and for all types of patent ductus arteriosuses.
Rapid reduction of the size of the left atrium and left ventricle by echocardiography is consistent with reduction of left-to-right shunt. Persistence of small residual shunts immediately after device placement in 29% of the patients (4 of 14) is of concern. However, in 2 of the 4 patients, the shunts (which were present immediately after device implantation) disappeared on follow-up. This is similar to the reduction in percent of residual shunts following implantation of Rashkind's device, as observed by Musewe and colleagues.22 Because of the lack of murmurs and because of reduction in the left atrial size, these shunts are small and probably are of no concern. Progressive endothelialization may result in further closure of the residual defects.
Encroachment of the ostium of the left pulmonary artery, causing obstruction to flow, reported with Rashkind's device23 was not seen in this small series. This is probably related to the less bulky nature of the counteroccluder that is on the pulmonary arterial end of the ductus. 
Addendum
Since the preparation of the manuscript, 21 additional patients (total of 35) underwent transcatheter occlusion of patent ductus arteriosus. Successful device implantation was feasible in 34 patients (97%). In the lone exception, the device was inadvertently dislodged while disconnecting the nylon thread, but the device was extracted out of the patient transvenously. In the remaining 34 patients, immediate and follow-up results remain similar to those of the first 14 patients.
